Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
17 Septiembre 2024 - 3:05PM
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global
biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic and cardiopulmonary diseases, today
announced key leadership appointments to drive its next phase of
development and operational success. Blai Coll, M.D., Ph.D., has
been promoted to Chief Medical Officer, replacing Mark Bach, M.D.,
Ph.D. as part of a planned succession, effective September 18. Dr.
Coll has served as Vice President of Clinical Development at
Structure since 2022, leading the GSBR-1290 program, Structure’s
oral small molecule GLP-1 agonist that is planned to enter Phase 2b
clinical development for obesity in the fourth quarter of 2024. In
addition, Ashley Hall, J.D., has been appointed to the newly
created position of Chief Development Officer, and will be
responsible for clinical development operations, project
management, regulatory affairs and quality assurance.
“Our expanded clinical leadership team strengthens our position
to efficiently execute as we move into Phase 2b development of
GSBR-1290 in the fourth quarter. In addition, we are building our
organization to advance our promising oral amylin compound into the
clinic as soon as possible,” said Raymond Stevens, Ph.D., Founder
and CEO of Structure Therapeutics. “Ms. Hall’s unique background in
regulatory strategy and clinical development operations will help
enable us to rapidly develop our oral small molecules for patients
with cardiometabolic diseases. Dr. Coll has a deep understanding of
the cardiometabolic clinical space and in his time at Structure, he
has led the rapid advancement of GSBR-1290. I would like to thank
Dr. Bach for his contributions over the last few years in
establishing the foundation for our clinical organization and
working closely with Dr. Coll as part of this planned
transition.”
About Blai Coll, M.D., Ph.D.Dr. Coll is a
physician-scientist with 15 years of experience in clinical
development. Prior to being promoted to Chief Medical Officer, Dr.
Coll was Vice President of Endocrine and Metabolism Clinical
Development at Structure Therapeutics, where he led the company’s
clinical development activities for GSBR-1290. Before joining
Structure, Dr. Coll was at Amgen where he held different leadership
positions in the cardiovascular group, including management of
lifecycle studies for Repatha® (open label extension studies with
more than 6,000 patients) and early development projects in the
cardiovascular space. Before joining Amgen, Dr. Coll served as
Medical Director at AbbVie, leading the late-stage atrasentan
clinical program for chronic kidney disease, including a Phase 3
multinational outcomes study.
About Ashley Hall, J.D. Ms. Hall has extensive
experience in global clinical development operations and regulatory
affairs at several companies, particularly in the development of
Repatha®, Nexletol®, and Nexlizet®, three therapies approved for
the management of hyperlipidemia and cardiovascular risk reduction.
Over the last 23 years, Ms. Hall has collaborated closely with
global regulatory authorities to navigate complex development and
operational processes for multiple successful large-scale,
multi-national Phase 3 clinical trials. Prior to joining
Structure Therapeutics, Ms. Hall served as Chief Development
Officer of Reneo Pharmaceuticals. Prior to Reneo, Ms. Hall was the
Chief Development Officer and Head of Global Regulatory Affairs at
Esperion Therapeutics, where she was responsible for the conduct of
five pivotal trials in low density lipoprotein cholesterol (LDL-C)
lowering in over 4,000 patients and a large cardiovascular outcomes
trial (CVOT). Ms. Hall was previously at Amgen, where she led the
global regulatory strategy and marketing applications for Repatha®
in 11 countries and regions, including the United States, Japan and
the European Union.
About Structure Therapeutics Structure
Therapeutics is a science-driven clinical-stage biopharmaceutical
company focused on discovering and developing innovative oral small
molecule treatments for chronic metabolic and cardiopulmonary
conditions with significant unmet medical needs. Utilizing its next
generation structure-based drug discovery platform, the Company has
established a robust GPCR-targeted pipeline, featuring multiple
wholly-owned proprietary clinical-stage small molecule compounds
designed to surpass the scalability limitations of traditional
biologic and peptide therapies and be accessible to more patients
around the world. For additional information, please
visit www.structuretx.com.
Forward Looking Statements This press
release contains “forward-looking statements” within the meaning of
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements, including, without limitation, statements concerning:
the Company’s future plans and prospects; and the timing of the
Company’s clinical development programs. In addition, when or if
used in this press release, the words and phrases “expect,” “plan,”
“potential,” “promising,” “to be,” and similar expressions and
their variants, as they relate to the Company may identify
forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Although the
Company believes the expectations reflected in such forward-looking
statements are reasonable, the Company can give no assurance that
such expectations will prove to be correct. Readers are cautioned
that actual results, levels of activity, safety, performance or
events and circumstances could differ materially from those
expressed or implied in the Company’s forward-looking statements
due to a variety of risks and uncertainties, which include, without
limitation, risks and uncertainties related to the Company’s
ability to advance GSBR-1290, LTSE-2578, ANPA-0073 and its other
therapeutic candidates, obtain regulatory approval of and
ultimately commercialize the Company’s therapeutic candidates,
competitive products or approaches limiting the commercial value of
the Company’s product candidates, the timing and results of
preclinical and clinical trials, the Company’s ability to fund
development activities and achieve development goals, the impact of
any global pandemics, inflation, supply chain issues, rising
interest rates and future bank failures on the Company’s business,
its ability to protect its intellectual property and other risks
and uncertainties described in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, as
filed with the SEC on March 8, 2024, the Quarterly Report on Form
10-Q filed with the SEC on August 8, 2024, and future reports the
Company may file with the SEC from time to time. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
Investors:Danielle KeatleyStructure
Therapeutics Inc.ir@structuretx.com
Media:Dan Budwick1ABDan@1abmedia.com
Structure Therapeutics (NASDAQ:GPCR)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Structure Therapeutics (NASDAQ:GPCR)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024